Connective tissue disorders often present unique diagnostic and therapeutic challenges due to their rarity and phenotypic heterogeneity. Clinicians have frequently struggled to define high-level concepts for rare connective tissue diseases, such as "refractory" or "severe" disease states. The European Reference Network (ERN) ReCONNET introduced the ReCONNET-ELICIT methodology to bridge these gaps. This approach harnesses collective intelligence for clinical facets. By integrating diverse expert perspectives, the framework ensures a comprehensive understanding of musculoskeletal conditions. Consequently, the methodology provides a structured pathway to achieve agreement where traditional clinical data might be scarce or inconsistent. Furthermore, it moves beyond the limitations of individual clinical judgment, which is inherently restricted by personal experience. As a result, the medical community can now utilize a more participatory and inclusive model. This article explores how this innovative consensus-building tool operates within rheumatology and rare disease management.

The Rationale for ReCONNET-ELICIT in Rare Connective Tissue Diseases

The primary motivation for ReCONNET-ELICIT stems from the difficulties in studying rare diseases. Standard clinical trials are often unfeasible because patient numbers are too low. Therefore, medical knowledge typically relies on expert consensus. However, traditional methods like the Delphi technique can suffer from dominance bias. ReCONNET-ELICIT solves these issues by creating a broader ecosystem for data gathering. It focuses on high-level concepts that currently lack standardized definitions. For instance, determining life-threatening organ involvement requires more than a single expert's view. By aggregating insights from a diverse group, the methodology achieves a depth of understanding previously impossible. This collective approach is essential for advancing the standard of care. Consequently, it allows for the development of more precise clinical guidelines. In addition, the framework supports identifying research priorities that reflect actual clinical needs. Ultimately, the goal is to improve patient outcomes by ensuring a shared, well-defined clinical vocabulary.

Composition and Diversity of the Expert Panel

A hallmark of ReCONNET-ELICIT is its emphasis on panel diversity. This process begins with the assembly of a large panel from various geographical backgrounds. This inclusivity is vital because rare connective tissue diseases may present differently across ethnicities. Moreover, clinicians in various regions might have access to different diagnostic tools. By involving participants from numerous countries, the methodology ensures the resulting consensus is globally relevant. Furthermore, involving a wide array of specialists ensures a multidisciplinary perspective. This is crucial for multisystemic diseases affecting several organ systems. Consequently, the panel's broad composition acts as a safeguard against narrow viewpoints. In addition, the participatory framework encourages clinicians to contribute their unique insights. This collaborative spirit enriches data and fosters community. Therefore, the resulting definitions represent the global medical collective. This diversity strengthens the validity of the final consensus.

Systematic Crowdsourcing and the Binning Process

The data collection phase of ReCONNET-ELICIT relies on modern digital tools. The process initiates with an online survey where participants suggest facets of a high-level concept. When defining "refractory disease," experts list biological markers and treatment failures. This phase captures variety without the constraints of meetings. Furthermore, the asynchronous nature allows experts to contribute at their own pace. Once initial responses are collected, they undergo systematic analysis. This involves a binning process where suggestions are recoded into broader categories. Consequently, redundant facets are consolidated for clarity. This analysis is consensus-driven, ensuring categories accurately reflect the underlying data. Moreover, it allows identifying emerging themes that might be overlooked. By transforming raw input into structured categories, the methodology builds a solid foundation for voting phases. This structured approach ensures final concepts are comprehensive and actionable.

Mitigating Dominance Bias in Consensus Building

One significant challenge in consensus-building is dominance bias. ReCONNET-ELICIT addresses this by using a structured voting system incorporating rating scales. After the binning process, the panel reviews the consolidated list of facets. Each member then votes on inclusion independently and anonymously. This anonymity is critical because it allows honest opinions without peer pressure. Furthermore, rating scales allow nuanced expression of agreement beyond simple votes. Consequently, the committee can identify facets with strong support. This structured approach ensures the final consensus reflects collective agreement rather than the views of a vocal minority. In addition, the methodology’s flexibility allows multiple rounds of voting if necessary. This iterative process refines concepts until a stable consensus is reached. By prioritizing transparency and equal participation, ReCONNET-ELICIT enhances the credibility of its outputs. As a result, the clinical definitions produced are more likely to be adopted globally.

Impact on Management of Rare Connective Tissue Diseases

The long-term impact of ReCONNET-ELICIT extends far beyond creating definitions. By providing a shared understanding, the methodology facilitates better communication between clinicians and researchers. For instance, standardized definitions allow more accurate patient stratification in clinical trials. Consequently, this can lead to more targeted therapies for rare connective tissue diseases. Furthermore, the methodology helps identify unmet needs and knowledge gaps. This guides future research toward critical areas of patient care. In addition, the framework’s flexibility makes it adaptable to various types of rare diseases. It can define diagnostic criteria, treatment response, or patient-reported outcomes. As the medical landscape evolves, tools like ReCONNET-ELICIT will be essential for integrating new evidence with expert insights. Moreover, the focus on collective agreement ensures management strategies are grounded in practical expertise. Ultimately, this approach empowers the medical community to provide consistent, high-quality care to patients with complex conditions.

What is the primary purpose of the ReCONNET-ELICIT methodology?

The primary purpose of ReCONNET-ELICIT is to gather systematic expert consensus on high-level, complex concepts in rare connective tissue diseases. Traditional data are often limited in these fields, making it difficult to define terms like "refractory disease." This methodology aggregates insights from a large, diverse panel of experts to create clear, shared definitions. Consequently, it helps improve clinical communication, research standardization, and the overall management of rare musculoskeletal conditions.

How does ReCONNET-ELICIT prevent a few experts from dominating the consensus?

ReCONNET-ELICIT prevents dominance bias by using an asynchronous, structured framework where participants contribute independently. During the crowdsourcing and voting phases, individuals provide their insights and ratings through online platforms without direct peer pressure. This anonymity ensures that every expert's perspective is weighted equally. Furthermore, the use of rating scales and consensus-driven binning processes ensures that the final output reflects the collective agreement of the group rather than a vocal minority.

Why is geographical diversity emphasized in this consensus-building process?

Geographical diversity is emphasized because rare connective tissue diseases can exhibit varied clinical presentations across different regions and healthcare systems. By involving experts from diverse geographical backgrounds, the methodology ensures that the resulting definitions are globally applicable. This inclusivity helps capture a wide range of clinical experiences and practices. Moreover, it prevents the consensus from being biased toward the standards of a single region, making the final concepts more robust and internationally relevant.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Arnaud L et al. Methodology for eliciting consensus on high-level concepts in rare connective tissue and musculoskeletal diseases (ReCONNET-ELICIT). Orphanet J Rare Dis. 2026 Jul 15. doi: 10.1186/s13023-026-04502-3. PMID: 42458497.